These CD34+ iMCs promote tumour growth by expression of the matrix metalloproteinases, MMP9 and MMP2, and the CC-chemokine receptor 1 (CCR1), and migrate towards the CCR1 ligand CCL9, highly increased in the tumour epithelium. Here, MMP9 is linked to neoplasm.